Results 21 to 30 of about 1,458 (171)

WEE1 inhibitor exerts synergistic effect with KRAS G12C inhibitor via MYBL2-RRM2 axis in KRAS^G12C-mutant lung cancer. [PDF]

Cell Death Dis
The clinical effect of KRAS G12C inhibitors (G12Ci) as monotherapy is poor, prompting the development of combination treatment strategies. Here, we demonstrate that the WEE1 kinase inhibitor (WEE1i), Adavosertib, can sensitize the effect of G12Ci through
Zhou C, Liu Y, Liu H, Lu J, Zhang B, Zhu L, Wang S, Lei H, Han B.   +8 more
europepmc   +2 more sources

Combined inhibition of ribonucleotide reductase and WEE1 induces synergistic anticancer activity in Ewing's sarcoma cells. [PDF]

BMC Cancer
Background Ewing’s sarcoma is a childhood bone and soft tissue cancer with poor prognosis. Treatment outcomes for Ewing’s sarcoma patients have improved only modestly over the past decades, making the development of new treatment strategies paramount. In
Ziener J, Henao-Restrepo JA, Leonhardi J, Sturm MJ, Becker S, Morales-Prieto DM, Milde T, Beck JF, Sonnemann J.   +8 more
europepmc   +2 more sources

WEE1 Inhibition as a Novel Therapeutic Strategy in Cutaneous T-Cell Lymphoma. [PDF]

Cancers (Basel)
Background/Objectives: Cutaneous T-cell lymphomas (CTCL), most commonly mycosis fungoides and Sézary syndrome, are rare non-Hodgkin lymphomas. Advanced disease responds poorly to current treatments, highlighting the need for new molecularly targeted ...
Özistanbullu D, Bahrami K, Doll M, Reichenbach G, Pöschl SM, Wilhelm R, Stege H, Zöller N, Winkler L, Jäger M, Nicolay JP, Quist SR, Kaufmann R, Meissner M, Schilling B, Kleemann J, Cinatl J, Kippenberger S.   +17 more
europepmc   +3 more sources

ROR1-PI3K/AKT signaling drives adaptive resistance to cell cycle blockade in TP53 mutated ovarian cancer

Cell Death and Disease
Drug resistance remains a major challenge to durable responses in ovarian cancer, the fifth leading cause of cancer-related death among women. In this study, we developed long-term resistant (lt-res, several months) pre-clinical models of two drugs ...
Juuli Raivola, Frida Rantanen, Alice Dini, Emilia Piki, Harlan Barker, Elina Multamäki, Franziska Bentz, Pia Sunkel, Aino-Maija Kiiski, Lassi Paavolainen, Astrid Murumägi, Daniela Ungureanu   +11 more
doaj   +2 more sources

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations

Frontiers in Medicine, 2021
p53 is among the most frequently mutated tumor suppressor genes given its prevalence in >50% of all human cancers. One critical tumor suppression function of p53 is to regulate transcription of downstream genes and maintain genomic stability by ...
Xiangbing Meng, Xiangbing Meng, Jason Z. Gao, Sean Michael T. Gomendoza, John W. Li, John W. Li, Shujie Yang, Shujie Yang   +7 more
doaj   +1 more source

Targeting WEE1 kinase as a p53-independent therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia

Cancer Cell International, 2023
Background Outcomes for patients with relapsed acute lymphoblastic leukemia (ALL) are poor and there is a need for novel therapies to improve outcomes.
Hayden L. Bell, Helen J. Blair, Mankaran Singh, Anthony V. Moorman, Olaf Heidenreich, Frederik W. van Delft, John Lunec, Julie A. E. Irving   +7 more
doaj   +1 more source

Treatment options for recurrent platinum-resistant ovarian cancer: A systematic review and Bayesian network meta-analysis based on RCTs

Frontiers in Oncology, 2023
BackgroundThere are a variety of treatment options for recurrent platinum-resistant ovarian cancer, and the optimal specific treatment still remains to be determined. Therefore, this Bayesian network meta-analysis was conducted to investigate the optimal
Juan Li, Guorong Zou, Wei Wang, Chen Yin, Haowen Yan, Shengpeng Liu   +5 more
doaj   +1 more source

CCNE1: A Cell Cycle Regulator That Influences Tumor Progression. [PDF]

Cancer Med
ABSTRACTCyclin E1 (CCNE1), a pivotal member of the cyclin family, governs the G1/S phase transition of the cell cycle by binding to and activating cyclin‐dependent kinase 2 (CDK2), thereby initiating DNA replication and driving S‐phase entry. In a broad spectrum of human malignancies—including breast, ovarian, gastric, and non‐small cell lung cancers ...
Yan L, Liu S, Li Y, He Q, Long C, Tang N, Zhou Y.   +6 more
europepmc   +2 more sources

Safety, pharmacokinetics, and clinical activity of adavosertib in combination with chemotherapy in Asian patients with advanced solid tumors : Phase Ib study [PDF]

, 2020
Background: The WEE1 inhibitor adavosertib (AZD1775) has been investigated in Western patients. Objective: This open-label Phase Ib study (NCT02341456) investigated the safety, pharmacokinetics, and clinical activity of adavosertib in combination with ...
Kato, Hidenori, Naito, Yoichi, Mugundu, Ganesh M., Lickliter, Jason D., de Souza, Paul, Kumar, Sanjeev, Park, Keunchil, Souza, Paul de (R16678), Kim, Sang-We, Bang, Yung-Jue   +9 more
core   +1 more source

Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors

Frontiers in Cell and Developmental Biology, 2023
Cell cycle checkpoint kinases serve as important therapeutic targets for various cancers. When they are inhibited by small molecules, checkpoint abrogation can induce cell death or further sensitize cancer cells to other genotoxic therapies. Particularly
Sargun Sokhi, Sargun Sokhi, Sargun Sokhi, Cody W. Lewis, Cody W. Lewis, Cody W. Lewis, Amirali B. Bukhari, Amirali B. Bukhari, Amirali B. Bukhari, Joanne Hadfield, Joanne Hadfield, Joanne Hadfield, Edric J. Xiao, Edric J. Xiao, Edric J. Xiao, Jeremy Fung, Jeremy Fung, Yea Jin Yoon, Yea Jin Yoon, Wen-Hsin Hsu, Wen-Hsin Hsu, Wen-Hsin Hsu, Armin M. Gamper, Armin M. Gamper, Armin M. Gamper, Gordon K. Chan, Gordon K. Chan, Gordon K. Chan   +27 more
doaj   +1 more source